Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation

Haihong Fang,Xinxu Xie,Peng Liu,Ying Rao,Yaru Cui,Shilin Yang,Jun Yu,Yingying Luo,Yulin Feng

DOI: https://doi.org/10.1016/j.biopha.2020.110862

2020-12-01

Abstract:<p>Ziyuglycoside II (ZGS II) is a major bioactive ingredient of <em>Sanguisorbae officinalis L</em>., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of ZGS II in cyclophosphamide-induced leukopenia in mice. The results showed that ZGS II significantly increased the number of total white blood cells and neutrophils in the peripheral blood. Flow cytometry analysis also showed a significant increase in the number of nucleated cells and hematopoietic stem and progenitor cells (HSPCs) including ST-HSCs, MPPs, and GMPs, and enhanced HSPC proliferation in ZGS II treated mice. The RNA-sequencing analysis demonstrated that ZGS II effectively regulated cell differentiation, immune system processes, and hematopoietic system-related pathways related to extracellular matrix (ECM)-receptor interaction, focal adhesion, hematopoietic cell lineage, cytokine-cytokine receptor interaction, the NOD-like receptor signaling pathway, and the osteoclast differentiation pathway. Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (<em>Cxcl12, Col1a2,</em> and <em>Sparc</em>) and the surface markers of neutrophilic precursors or neutrophils (<em>Ngp</em> and <em>CD177</em>). Collectively, these data suggest that ZGS II protected against chemotherapy-induced leukopenia by regulating HSPC proliferation and differentiation.</p>

pharmacology & pharmacy,medicine, research & experimental